In 32 male Wistar rats fed a high-fat diet for eight weeks, exogenous spexin returned triglycerides to control levels, reduced hepatic steatosis and restored glutathione peroxidase activity, without altering body or liver weight. Sequencing showed the high-fat diet raised hepatic miR-92a-3p and spexin normalized it. Spexin also induced miR-455-5p, suppressed miR-486, normalized NLRP3 and Gasdermin-D (pyroptosis markers) and reversed BAX, an apoptosis marker. It did not restore the let-7 family or the NRF2/HO-1 antioxidant axis.

This is animal evidence only, and no human recommendation follows from it. Spexin is a peptide hormone not available as a supplement or approved therapy, so adults cannot act on this directly. The finding is mechanistically interesting: the protection looks selective, targeting inflammatory cell-death pathways rather than the lipogenic program or weight, which suggests a partial hepatoprotective effect that may be separable from fat loss. That distinction matters because the leading fatty-liver therapies, such as GLP-1 drugs and weight loss, work largely through reducing adiposity. Limits are substantial: eight animals per group, male rats only, a single short diet period, and miRNA changes that are correlative rather than proven causal. Whether miR-92a-3p mediates the benefit was not tested by knockdown. Earlier rodent work has linked spexin to improved lipid handling, so this is incremental, adding a miRNA layer to a known story. Treat it as hypothesis-generating preclinical work, years from any human test.